Type 2 diabetes is rising twice as fast in women under 40, and the primary driver is a pregnancy complication most health systems stop tracking after delivery
Gestational diabetes depletes beta-cell reserve. When follow-up fails, that depletion quietly progresses to type 2 diabetes within a decade
More than half of at-risk women never receive the one annual blood test that could catch conversion early
South Asian, Hispanic, and Afro-Caribbean women convert faster and at lower body weights, yet clinical risk tools were not built for them
The screening exists. The prevention tools exist. The gap is follow-through.
Between 2017-18 to 2023-24, type 2 diabetes cases in women younger than 40 increased by 47%, while women between the ages of 40 and 79 experienced an increase of 22% in the same period. Among men under 40, the increase was 34%. According to Diabetes UK, the figures released in May 2026 demonstrate the prevalence of a failing preventative strategy within health services whereby at-risk women identified through pregnancy are not provided with the follow-up that would prevent type 2 diabetes from occurring.
Type 2 diabetes diagnosed in individuals prior to the age of 40 does not have the characteristics of diabetes diagnosed later in life. It has more rapid beta-cell deterioration, often requiring drug therapy earlier in its development, and cardiovascular risk begins to accumulate sooner than for older-onset type 2 diabetes. The issue of why more women than expected were diagnosed has an easy explanation.
Gestational diabetes mellitus (GDM) is by far the most important modifiable risk factor in this cohort of patients. GDM usually occurs between weeks 24-28, secondary to physiological insulin resistance resulting from maternal hormones, such as human placental lactogen and progesterone. In many cases, the pancreas is able to maintain normoglycaemia via increasing insulin release from the beta cells. In patients with GDM, the body fails to cope adequately with the increased demands for insulin.1
Although blood glucose levels will often return to normal after the birth of the child, the inherent metabolic issues that facilitated the development of GDM does not go away with the delivery.
Many pregnant women with GDM have an existing impairment of their first-phase insulin response. This relates to the initial insulin peak following exposure to glucose. The effect of this impairment only becomes clear during the period of heightened insulin demands seen during pregnancy. Post-partum, the block is no longer present; however, the pancreatic beta-cell reserve is diminished from overcompensation throughout pregnancy.
The consequence is an insulin-producing cell line (Beta cells) that has been rendered suboptimal by the time the postpartum period arrives. Insulin resistance due to excessive fat stores, physical inactivity, or more pregnancies continues to exacerbate depletion in the following years. Type 2 diabetes in a patient with previous GDM is only the next step in a process that began much earlier and was not imposed externally.
Type 2 diabetes after GDM carries a substantially increased risk in women requiring insulin than in women who were managed conservatively. The magnitude of this risk increase has been quantified by a systematic review and meta-analysis, which found that it is around 3.5 times greater. An umbrella analysis performed on 15 systematic reviews confirmed this risk ratio (3.7-4.4) in insulin-requiring GDM patients.2,3
Not all women with previous GDM have a similarly high likelihood of developing type 2 diabetes postpartum. Risk factors include several clinical parameters:
Insulin requirement during the GDM pregnancy
GDM diagnosed before week 24, suggesting pre-existing glucose dysregulation
Elevated fasting glucose or HbA1c at the time of GDM diagnosis
High BMI or significant gestational weight gain
Family history of type 2 diabetes
Multiple prior pregnancies complicated by GDM
Ethnicity can serve as an independent risk factor, which is often overlooked in risk assessment processes. South Asian, Hispanic, and Afro-Caribbean women have a considerably higher conversion rate from GDM to type 2 diabetes compared to their Caucasian counterparts, at a lower BMI. Such a phenomenon can be explained by dissimilarities in fat distribution, where individuals with specific ethnic backgrounds have visceral and ectopic fat accumulation in spite of relatively low body mass index values.1
Risk stratification techniques have been predominantly validated on Caucasian patient cohorts living in Europe and North America. FINDRISC is a score calculating 10-year risk of developing type 2 diabetes based on eight easily measurable risk factors including BMI, waist circumference, physical activity, dietary habits, and family history.4 QDiabetes-2018 is another instrument predicting a person's risk of diabetes development and has proven its value in validating GDM history as a predictive variable in UK populations.5
The discussed risk instruments could be regarded as valuable references when communicating risk to patients. Nevertheless, additional work on population-specific risk validation remains to be done for South Asians, Middle-Easterners, and Sub-Saharan Africans in particular.
Most importantly, there is currently a need for systematic post-delivery screening in these women. Waiting for symptoms to manifest is not a clinically sound strategy. Prediabetes and early type 2 diabetes are asymptomatic disorders. Peripheral neuropathy or retinopathy will only become apparent after several years of accumulated microvascular damage.
According to the American Diabetes Association, Standards of Care 2024, every woman with prior gestational diabetes should go through a structured metabolic screening post-delivery:6
4 to 12 weeks post-partum: An OGTT involving 75g glucose load. In favor of the OGTT compared to the HbA1c test, the latter is not accurate enough during the early post-delivery period, as increased red blood cell turnover associated with pregnancy and post-delivery bleeding can persistently suppress HbA1c levels.6
Regular follow-ups every 1 to 3 years: Gradual transition to either HbA1c or fasting plasma glucose tests. Even if the first OGTT after delivery turns out negative, subsequent screening should be done in accordance with guidelines in community settings.6
3-6 years post-delivery: Continued follow-up is crucial. This period marks the highest probability of transitioning from GDM to type 2 diabetes.2,3
Prior to any future pregnancy: Screening for HbA1c before conception to avoid exposure to high glucose levels during the very early stages of pregnancy.
However, despite such clear guidelines, the NHS National Audit for 2024/25 for GDM showed that less than 57% of women having had a previous diagnosis of GDM underwent an annual HbA1c screening, and less than 4.5% were referred for a diabetes prevention program.
FINDRISC and QDiabetes could be helpful in such cases for identifying those patients who require a more aggressive approach to management via lifestyle modifications or pharmacological interventions.4,5 These tools have been validated and can be freely accessed by health professionals. Clinicians should use these tools keeping in mind that they may have some limitations due to their populations' demographic background. Research on population-specific validations is ongoing.
For the newborn, complications associated with poorly managed GDM include:
Macrosomia, which can complicate delivery and increase the likelihood of birth injury
Neonatal hypoglycaemia in the immediate postpartum period
Respiratory distress syndrome
Neonatal jaundice
Higher long-term risk of obesity and type 2 diabetes in childhood and adult life
For the mother, risks extend beyond the pregnancy itself:
Preeclampsia during the index pregnancy
Higher likelihood of caesarean delivery
Recurrent GDM in subsequent pregnancies
Elevated cardiovascular disease risk, which current evidence suggests operates largely independently of whether type 2 diabetes subsequently develops7
Progression to type 2 diabetes, concentrated in the first decade postpartum
Because prediabetes and early type 2 diabetes are usually asymptomatic, scheduled surveillance matters more than symptom-triggered visits. However, the following should prompt an earlier unscheduled review:
Persistent thirst or markedly increased urination in the months after delivery, beyond what is expected during breastfeeding
Unexplained fatigue not accounted for by the demands of early parenthood
Blurred vision
Slow healing of minor wounds or cuts
Tingling, numbness, or burning in the hands or feet
Recurrent infections, particularly urinary tract or fungal infections
Women who have not been contacted for scheduled postpartum metabolic review should not wait. Initiating that conversation with a treating physician or primary care provider is clinically warranted given the conversion risk data.
Formal correspondence from Diabetes UK to the Women's Health Minister of the UK has called for regular annual tests for HbA1c for women post-GDM, higher referral rates to diabetes prevention programs, and measures of accountability against health services that do not provide adequate follow-up. Almost one third of women diagnosed with GDM felt abandoned by the health services after childbirth.
The International Federation of Gynecology and Obstetrics states that pregnancy should be seen as a lifelong metabolic risk indicator. Once a woman has developed GDM in any pregnancy, she will be prone to type 2 diabetes throughout her life. As such, the healthcare systems need to respond to this reality effectively.1
This expectation remains unfulfilled globally. The gaps in post-GDM care highlighted through the UK NHS audit are not a characteristic of one particular healthcare system alone. Postpartum GDM screening in developing nations is even more sporadic and lacks population-specific risk assessment tools. This has resulted in an increase in type 2 diabetes cases in women by a significant 47%.
Adam, S., McIntyre, H. D., Tsoi, K. Y., Kapur, A., Ma, R. C., Dias, S., ... & McAuliffe, F. M. (2023). Pregnancy as an opportunity to prevent type 2 diabetes mellitus: FIGO Best Practice Advice. International Journal of Gynecology and Obstetrics, 160(Suppl. 1), 56-67. https://doi.org/10.1002/ijgo.14537
Rayanagoudar, G., Hashi, A. A., Zamora, J., Khan, K. S., Hitman, G. A., & Thangaratinam, S. (2016). Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women. Diabetologia, 59(7), 1403-1411. https://doi.org/10.1007/s00125-016-3927-2
Chen, K., Tang, L., Wang, X., Li, Y., Zhang, X., Cui, S., Chen, W., Jin, Z., & Zhu, D. (2024). Prevalence and risk factors for type 2 diabetes mellitus in women with gestational diabetes mellitus: a systematic review and meta-analysis. Frontiers in endocrinology, 15, 1486861. https://doi.org/10.3389/fendo.2024.1486861
Lindstrom, J., & Tuomilehto, J. (2003). The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care, 26(3), 725-731. https://doi.org/10.2337/diacare.26.3.725
Hippisley-Cox, J., & Coupland, C. (2017). Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study. BMJ, 359, j5019. https://doi.org/10.1136/bmj.j5019
American Diabetes Association. (2024). 15. Management of diabetes in pregnancy: Standards of Care in Diabetes 2024. Diabetes Care, 47(Suppl. 1), S282-S294. https://doi.org/10.2337/dc24-S015
Burlina, S., Dalfra, M. G., Chilelli, N. C., & Lapolla, A. (2016). Gestational diabetes mellitus and future cardiovascular risk: An update. International Journal of Endocrinology, 2016, Article 2070926. https://doi.org/10.1155/2016/2070926
